FNDC5 and type 2 diabetes mellitus: The present findings suggest that the role of irisin as a protective myo‐adipokine in atypical metabolic situations needs further examination, but provides promising support for the potential pharmacotherapeutic use of irisin in the treatment of obesity and type 2 diabetes.